Abstract:

Objective: In recent years, many studies have been conducted on non-invasive diagnostic methods to evaluate fibrosis in patients with chronic hepatitis B (CHB). However, liver biopsy is still considered the gold standard. In this study, we aimed to present the biopsy results and non-invasive fibrosis scoring findings of CHB patients and to determine biopsy in terms of starting treatment. Material and Methods: Twenty patients who were followed up in our hospital for infectious diseases outpatient clinic between April 2017 and April 2019 due to CHB and who underwent percutaneous liver biopsy in the interventional radiology unit were included in the study. Demographic features, alanine aminotransferase, aspartate aminotransferase, HBV-DNA levels, platelet counts were examined. APRI (AST to Platelet Ratio Index) and FIB-4 (Fibrosis-4) values were calculated. Results: The mean fibrosis score of the patients was 2±0.67, the average histological activity score (HAI) was 6.79±2.49, and the mean platelet counts were 235.35±54.84 10³ / μL. The average of APRI (AST to Platelet Ratio Index) value was calculated as 0.53 ± 0.36 and the average of FIB-4 (Fibrosis-4) value was calculated as 0.97±0.51. In statistical analysis, there was no significant correlation between HAI - APRI, HAI - FIB-4, fibrosis score - APRI, fibrosis score - FIB-4 (P values 0.473, 0.595, 0.078, 0.718, respectively). Conclusion: In our study, no correlation with the degree of fibrosis was detected in the statistical evaluation in terms of APRI and FIB-4 values. We think this is due to the small number of our cases. We believe that this study, in which we present our data in detail, will contribute to meta-analysis.

Keywords: